
PREDICTING LUNG CANCER PATIENT PROGNOSIS WITH LARGE LANGUAGE MODELS

Danqing Hu
Zhejiang Lab
Hangzhou, Zhejiang, China
hudq@zhejianglab.com

Bing Liu
Peking University Cancer Hospital
and Institute
Beijing, China
liubing983811735@126.com

Xiang Li
Peking University Cancer Hospital
and Institute
Beijing, China
xiangli@bjmu.edu.cn

Xiaofeng Zhu
Zhejiang Lab
Hangzhou, Zhejiang, China
andy.zhu@zhejianglab.com

Nan Wu
Peking University Cancer Hospital
and Institute
Beijing, China
nanwu@bjmu.edu.cn

ABSTRACT

Prognosis prediction is crucial for determining optimal treatment plans for lung cancer patients. Traditionally, such predictions relied on models developed from retrospective patient data. Recently, large language models (LLMs) have gained attention for their ability to process and generate text based on extensive learned knowledge. In this study, we evaluate the potential of GPT-4o mini and GPT-3.5 in predicting the prognosis of lung cancer patients. We collected two prognosis datasets, i.e., survival and post-operative complication datasets, and designed multiple tasks to assess the models' performance comprehensively. Logistic regression models were also developed as baselines for comparison. The experimental results demonstrate that LLMs can achieve competitive, and in some tasks superior, performance in lung cancer prognosis prediction compared to data-driven logistic regression models despite not using additional patient data. These findings suggest that LLMs can be effective tools for prognosis prediction in lung cancer, particularly when patient data is limited or unavailable.

Keywords Large language models · Lung cancer · Survival prediction · Post-operative complication prediction

1 Introduction

Lung cancer continues to be the leading cause of cancer-related mortality worldwide [1]. For patients diagnosed with early-stage lung cancer, surgical resection offers the only potential cure [2]. Accurately predicting post-operative prognosis, including complications and survival, is essential for clinicians to optimize treatment strategies. Such predictions enable clinicians to implement early interventions and develop personalized follow-up plans, ultimately improving patient outcomes.

To predict prognosis accurately, researchers often rely on data-driven methods to develop prediction models. Early efforts involved combining patients' clinical features with statistical approaches to build predictive models and nomograms [3, 4, 5, 6]. For censored survival data, the Cox proportional hazards model was commonly used for survival prediction [3, 4]. To uncover nonlinear relationships among clinical variables, machine learning techniques such as random forests, random survival forests, support vector machines, and survival support vector machines were employed, which enhanced model performance [7, 8, 9, 10, 11, 12, 13]. With the rapid advancement of deep learning, these techniques have become the leading and most effective tools for developing prognosis prediction models [14, 15, 16, 17, 18, 19, 20]. Despite their success in cancer prognosis, these data-driven methods have a critical limitation: they require substantial amounts of clinical data, limiting their applicability in scenarios where such data is limited or unavailable.

Recently, large language models (LLMs) like ChatGPT [21] and GPT-4 [22] have gained significant global attention for their advanced text-generation capabilities. Trained on extensive datasets, these models can tackle new tasks using zero-shot, one-shot, or few-shot prompts without requiring updates to their parameters [23]. The integration of reinforcement learning from human feedback (RLHF) further enhances LLMs, enabling them to generate content that is both safe and consistent with human expectations [24]. This advancement has led to a significant shift in natural language processing (NLP) research and is beginning to impact clinical prediction research [25, 26, 27, 28, 29].

By utilizing medical knowledge acquired from extensive training data, LLMs have shown promise in diagnosing and assessing patient prognoses. While some studies have explored the use of LLMs for predicting clinical prognoses such as readmission, length of hospital stay, and mortality, their performance has generally not surpassed that of traditional machine learning models [30, 31, 32, 33]. In this study, we aim to leverage the large language models to predict the prognosis of lung cancer patients. We collected two prognosis datasets, i.e., survival and post-complication data, from the Department of Thoracic Surgery II, Peking University Cancer Hospital and Institute. GPT-4o mini and GPT-3.5 were employed to make prognosis predictions based on patients’ clinical data. Our experimental results demonstrate that LLMs with a zero-shot prompt can outperform baseline logistic regression models in lung cancer prognosis prediction.

2 Materials and methods

2.1 Prognosis datasets

- **Survival dataset (SD)** We gathered a survival dataset from 1,277 lung cancer patients who underwent pulmonary resections at Peking University Cancer Hospital. This dataset includes patient demographics, medical history, surgical information, pathological characteristics of the primary tumor and lymph nodes, and the pathological TNM stage. To ensure the accuracy and reliability of the data, clinicians manually recorded all clinical information. Follow-up data, including the event indicator (survival or not) and the timing of the event or censoring, were also documented by the clinicians.
- **Post-operative complication dataset (PCD)** We also included 593 lung cancer patients who underwent curative pulmonary resection in a separate post-operative complication dataset. All patients were over 70 years old and had no distant metastases. This dataset captures patient demographics, disease history, pre-operative examinations, surgical information, and the pathological TNM stage. Post-operative complications recorded include atelectasis, pleural effusion, asthma attack, lung infection, pulmonary embolism, deep vein thrombosis, arrhythmia, and angina. Clinicians manually collected all clinical data and complications from electronic medical records.

Ethical approval for this study was granted by the Ethics Committee of Peking University Cancer Hospital (2022KT128) before this study.

2.2 Study design

This study aims to leverage large language models (LLMs) to predict the prognosis of lung cancer patients. The overall study design is presented in Figure 1. We utilized the survival and post-operative complication datasets to generate prompts as input for the LLMs to obtain the predicted results. Additionally, we trained logistic regression models on these datasets to serve as the baselines. For survival prediction, we establish 5 prediction tasks, i.e., 1-year, 2-year, 3-year, 4-year, and 5-year survival predictions. For complication prediction, we predicted the risk of each of the eight complications and also combined these complications into a single label to predict.

2.3 Prompt design

The prompt templates of survival and post-operative complication prediction are shown in Figure 2. They consist of 4 elements, i.e., Role, Task, Patient data, and Instruction.

- **Role** This element defines the role that LLMs should adopt to generate responses for specific tasks. In this study, we instructed the LLMs to act as thoracic surgeons, responsible for assessing a patient’s prognosis and determining the appropriate treatment plan.
- **Task** This element specifies the prognosis prediction tasks assigned to the LLMs. For survival prediction, the LLMs were instructed to estimate the likelihood that a patient’s survival would exceed N year(s) where $N = \{1, 2, 3, 4, 5\}$. For complication prediction, the LLMs were tasked with predicting the likelihood of a patient developing one specific complication or any of the eight complications in our dataset.




Figure 1: Overall study design.

- **Patient data** This element details the patient clinical data used for evaluation by the large language models (LLMs). For survival prediction, we provided information on patient demographics, medical history, surgical information, pathological characteristics of the primary tumor and lymph nodes, and the pathological TNM stage. For complication prediction, the data included patient demographics, disease history, lung function tests, surgical information, histology, and the pathological TNM stage. The specific data items are illustrated in Figures 2(a) and 2(b).
- **Instruction** In this element, we instructed the LLMs to use the Chain-of-Thought strategy to reason step by step in estimating likelihoods. Additionally, the LLMs were directed to provide their responses in JSON format with key-value pairs, such as "Step by step explanation": "<string>", "Answer": "<float>".

2.4 Experimental setup

In this study, we employed GPT-4o mini (version gpt-4o-mini-2024-07-18) and GPT-3.5 (version gpt-3.5-turbo-1106) to predict the prognoses of lung cancer patients, accessed via the OpenAI API.

For survival prediction, we selected patients who had sufficient follow-up duration for each prediction task. For instance, in the 1-year survival prediction, we included patients who either experienced the event or had no event but were censored after more than one year. Based on the timing of events and censoring, we then assigned 1-year survival labels to the selected patients.

To provide a baseline comparison, we also developed logistic regression (LR) models using the collected datasets. For survival prediction, we implemented a 10-fold cross-validation strategy to split the survival dataset into training-validation and test sets. Within each fold iteration, we performed an additional 5-fold cross-validation on the 9-fold training-validation set to optimize hyperparameters, followed by retraining the model on this set using the selected hyperparameters. The trained model was then evaluated on the 1-fold test set. For complication prediction, we applied the same training, validation, and testing approach as used for survival prediction when predicting combined complications. However, when predicting specific complications, we used a 5-fold cross-validation to split the dataset, followed by a 3-fold cross-validation for hyperparameter tuning, due to the limited number of positive samples for some complications.

Role

You are an experienced thoracic oncology surgeon working in a hospital surgery center and you are assessing lung cancer patients for their further treatment.

Task

Your task is to analyze the patient's medical data and then estimate the likelihood that the patient's overall survival will exceed 1 year.

Patient data

Patient's medical data:

Age: 55 years old
 Gender: Female
 Smoking: No
 Drinking: No
 Family tumor history: Yes
 Surgery type: Lobectomy
 Tumor location: Left lower lobe
 Tumor size: 2.5 cm
 Histology: Adenocarcinoma
 Grade: Poorly differentiated
 Vessel carcinoma embolus: No
 Pleural invasion: Yes

Lymph node station 1L: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 1R: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 2L: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 2R: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 2R and 4R: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 3A: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 3P: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 4L: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 4R: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 5: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 6: 0 metastatic lymph node / 1 collected lymph node
 Lymph node station 7: 0 metastatic lymph node / 1 collected lymph node
 Lymph node station 8: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 9: 0 metastatic lymph node / 1 collected lymph node
 Lymph node station 10: 0 metastatic lymph node / 2 collected lymph nodes
 Lymph node station 11: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 12: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 13: 0 metastatic lymph node / 0 collected lymph node
 Lymph node station 14: 0 metastatic lymph node / 0 collected lymph node
 Pathological TNM stage: pT1cN0M0

Instruction

Think step by step and give your response in JSON format using the provided template. Please respond with only a floating-point number between 0 and 1 for "Answer", where a higher value suggests a higher likelihood that the patient's overall survival will exceed 1 year.

JSON response template:

```
{
  "Step by step explanation": "<string>",
  "Answer": "<float>"
}
```

(a)

Role

You are an experienced thoracic oncology surgeon working in a hospital surgery center and you are assessing lung cancer patients for their further treatment.

Task

Your task is to analyze the patient's medical data and then estimate the patient's likelihood of developing any post-operative complications, including atelectasis, asthma attack, pleural effusion, lung infection, pulmonary embolism, deep vein thrombosis, cardiac arrhythmia, and angina.

Patient data

Patient's medical data:

Age: 72 years old
 Gender: Female
 Height: 152.0 cm
 Weight: 54.0 kg
 Smoking: No
 Tuberculosis history: No
 Diabetes: Yes
 Thoracic surgery history: No
 Pre-operative treatment: No
 Pulmonary disease: No
 ThRCRI score: 0.0
 ASA class: 2
 FEV1/FVC: 0.78
 FEV1: 1.71 L
 MVV: 0.86
 DLCO: 1.02
 Pre-operative length of stay: 7 days
 Surgery type: Sublobar resection
 Surgery approach: MIS or VATS
 Surgery duration: 270 minutes
 Intraoperative bleeding volume: 100 ml
 Lymph node dissection type: Selective lymph node dissection
 Number of lymph nodes dissected: 9
 Number of lymph node stations dissected: 5
 Number of mediastinal lymph nodes dissected: 1
 Number of mediastinal lymph node stations dissected: 2
 Tumor location: Right lung, Upper lobe, Peripheral
 Tumor size: 0.3 cm
 Histology: Adenocarcinoma
 Pathological TNM stage: pT1aN0

Instruction

Think step by step and give your response in JSON format using the provided template. Please respond with only a floating-point number between 0 and 1 for "Answer", where a higher value suggests a higher likelihood that the patient will develop any post-operative complication.

JSON response template:

```
{
  "Step by step explanation": "<string>",
  "Answer": "<float>"
}
```

(b)

Figure 2: Prompt templates. (a) 1-year survival prediction prompt template, (b) Combined complication prediction prompt template

We evaluated model performance using two metrics: the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC).

3 Results

3.1 Prognosis data

In short-term survival prediction tasks, the number of patients who experienced events is relatively small, resulting in data imbalance. For long-term survival prediction tasks, fewer patients had sufficiently long follow-up periods, leading

Table 1: The statistics of the survival data.

Clinical feature	1-year survival (1277)	2-year survival (1122)	3-year survival (970)	4-year survival (815)	5-year survival (669)
Age (Mean)	60.14	60.12	60.20	60.24	60.41
Gender (Male/Female)	794 / 483	701 / 421	608 / 362	512 / 303	424 / 245
Smoking history (Yes/No)	698 / 588	610 / 512	534 / 436	445 / 370	368 / 301
Drinking history (Yes/No)	364 / 913	311 / 811	272 / 698	230 / 585	194 / 475
Family history (Yes/No)	179 / 1098	153 / 969	134 / 836	105 / 710	87 / 582
Surgery type					
Wedge resection	40	38	35	30	22
Segmentectomy	2	2	1	1	0
Lobectomy	1109	964	833	707	579
Bilobectomy	83	80	68	50	44
Pneumonectomy	39	34	31	25	22
Others	4	4	2	2	2
Tumor location					
RUL	415	372	313	261	217
RML	79	68	61	45	41
RLL	258	229	205	174	146
LUL	283	246	209	179	140
LLL	204	178	157	134	108
RC	22	17	16	15	13
LC	16	12	9	7	4
Tumor size (Mean)	3.17	3.20	3.23	3.28	3.40
Histology					
Adenocarcinoma	805	702	611	514	419
Squamous cell carcinoma	403	353	298	251	210
Adenosquamous carcinoma	17	17	15	12	11
Large cell carcinoma	24	24	24	22	17
Others	28	26	22	16	12
Grade					
Poorly differentiated	506	455	408	353	307
Moderately differentiated	549	503	426	346	275
Well differentiated	222	164	136	116	87
Vessel carcinoma embolus (Yes/No)	185 / 1092	165 / 957	136 / 834	124 / 691	104 / 565
Pleural invasion (Yes/No)	508 / 769	469 / 653	430 / 540	355 / 460	293 / 376
NLN station 1L (Metastatic/Collected)	0 / 9	0 / 7	0 / 7	0 / 4	0 / 0
NLN station 1R (Metastatic/Collected)	18 / 233	18 / 228	18 / 212	18 / 209	18 / 176
NLN station 2L (Metastatic/Collected)	1 / 4	1 / 3	1 / 2	1 / 2	1 / 2
NLN station 2R (Metastatic/Collected)	67/1057	62 / 967	60 / 821	51 / 727	50 / 657
NLN station 2R+4R (Metastatic/Collected)	151 / 1811	128 / 1534	114 / 1210	104 / 907	96 / 638
NLN station 3A (Metastatic/Collected)	35 / 488	33 / 462	32 / 431	32 / 359	31 / 281
NLN station 3P (Metastatic/Collected)	12 / 160	12 / 154	8 / 127	8 / 109	8 / 84
NLN station 4L (Metastatic/Collected)	38 / 541	30 / 483	27 / 442	22 / 402	19 / 322
NLN station 4R (Metastatic/Collected)	162 / 1723	155 / 1633	150 / 1489	141 / 1372	135 / 1235
NLN station 5 (Metastatic/Collected)	64 / 903	55 / 791	50 / 663	48 / 595	45 / 491
NLN station 6 (Metastatic/Collected)	92 / 1218	86 / 1091	67 / 949	60 / 820	52 / 624
NLN station 7 (Metastatic/Collected)	317 / 5526	282 / 4920	254 / 4161	246 / 3658	223 / 2995
NLN station 8 (Metastatic/Collected)	13 / 376	12 / 359	11 / 298	11 / 253	11 / 233
NLN station 9 (Metastatic/Collected)	27 / 1495	27 / 1354	25 / 1203	25 / 1041	23 / 854
NLN station 10 (Metastatic/Collected)	222 / 3181	208 / 2867	188 / 2534	177 / 2211	167 / 1890
NLN station 11 (Metastatic/Collected)	100 / 1630	87 / 1406	77 / 1233	72 / 1047	68 / 883
NLN station 12 (Metastatic/Collected)	450 / 3501	411 / 3162	372 / 2757	336 / 2335	303 / 1986
NLN station 13 (Metastatic/Collected)	225 / 1989	189 / 1594	162 / 1298	141 / 1059	122 / 790
NLN station 14 (Metastatic/Collected)	75 / 768	69 / 703	62 / 630	58 / 590	50 / 483
pT1 (1a/1b/1c)	80 / 316 / 400	69 / 277 / 354	57 / 235 / 317	43 / 199 / 250	33 / 147 / 202 /
pT2 (2a/2b)	228 / 123	195 / 112	165 / 95	149 / 88	129 / 80
pT3	91	80	70	61	55
pT4	39	35	31	25	23
pN (0/1/2/3)	795 / 224 / 246 / 12	693 / 199 / 218 / 12	589 / 172 / 197 / 12	473 / 149 / 183 / 10	372 / 124 / 163 / 10
Survival status (Alive/Dead)	1226 / 51	991 / 131	770 / 200	553 / 262	383 / 286

RUL: right upper lobe, RML: right middle lobe, RLL: right lower lobe, LUL: left upper lobe, LLL: left lower lobe, RC: right central, LC: left central, NLN: number of lymph nodes.

to a smaller sample size. As more events occur over longer periods, the issue of data imbalance is alleviated. Table 1 presents the statistics of the survival data.

Table 2 displays the statistics for the post-operative complication data. Complications such as asthma attacks, pulmonary embolism, and deep vein thrombosis were observed in only a few patients, resulting in a significant data imbalance.

3.2 Predictive performance

Table 3 presents the predictive performance of the LR, GPT-3.5, and GPT-4o mini models for the survival prediction tasks. GPT-4o mini consistently outperformed GPT-3.5 and the LR models in terms of AUROC values, except for the

Table 2: The statistics of the post-operative complication data

Characteristic	Statistic	Characteristic	Statistic
Age (Mean)	73.53	NLN dissected (Mean)	14.58
Gender (Male/Female)	323 / 270	NLNS dissected (Mean)	5.80
Height (Mean)	162.23	NMLN dissected (Mean)	7.92
Weight (Mean)	64.75	NMLNS dissected (Mean)	3.01
Smoking (Yes/No)	265 / 328	Tumor location	
Tuberculosis history (Yes/No)	54 / 539	Up/Middle or Bottom	337 / 256
Diabetes (Yes/No)	107 / 486	Left/Right	263 / 330
Thoracic surgery history (Yes/No)	38 / 555	Peripheral/Central	539 / 54
Pre-operative treatment (Yes/No)	43 / 550	Tumor size (Mean)	2.79
Pulmonary disease (Yes/No)	35 / 558	Histology	
ThRCRI score		Adenocarcinoma	451
0	464	Squamous cell carcinoma	115
1-1.5	121	Adenosquamous carcinoma	3
2-2.5	0	Large cell carcinoma	6
>2.5	8	Small cell carcinoma	10
ASA class (I/II/III)	28 / 458 / 107	Others	9
FEV1/FVC (Mean)	0.733	pT1 (1a/1b/1c)	39 / 136 / 93
FEV1 (Mean)	3.06	pT2 (2a/2b)	221 / 30
MVV (Mean)	0.80	pT3	60
DLCO (Mean)	0.88	pT4	14
Pre-operative length of stay (Mean)	3.9	pN (x/0/1/2)	44 / 447 / 41 / 61
Surgery type		Post-operative complication	
Wedge	84	Atelectasis	44
Sublobar	22	Asthma attack	9
Lobectomy	484	Pleural effusion	18
Others	3	Lung infection	42
Surgery approach		Pulmonary embolism	6
MIS or VATS	296	Deep vein thrombosis	6
Thoracotomy	297	Arrhythmia	88
Operation duration (Mean)	155.99	Angian	12
Intraoperative bleeding volume (Mean)	100.11	Combined	178
Lymph node dissection type			
Selective	414		
Systematic	135		
None	44		

ThRCRI: thoracic revised cardiac risk index, ASA: American Society of Anesthesiologists, FEV1: forced expiratory volume in the first second, FVC: forced vital capacity, MVV: maximal voluntary ventilation, DLCO: diffusing capacity of the lungs for carbon monoxide, MIS: minimally invasive surgery, VATS: video-assisted thoracoscopic surgery, NLN: number of lymph nodes, NLNS: number of lymph node stations, NMLN: number of mediastinal lymph nodes, NMLNS: number of mediastinal lymph node stations.

3-year survival prediction, where the LR model showed slightly better results. Regarding AUPRC, GPT-4o mini also delivered competitive performance, particularly in the 1-year, 2-year, and 5-year survival predictions, compared to LR and GPT-3.5. On average, GPT-4o mini achieved the highest predictive performance, improving the AUROC by 1.4% and the AUPRC by 2.5%. Figure 3 provides a visual comparison of the models' AUROC and AUPRC values.

For the post-operative complication prediction tasks, the GPT-4o mini model achieved the highest AUROC values in 5 tasks, while the LR model performed best in the remaining 4 tasks. In terms of AUPRC, GPT-3.5 delivered the best results in 5 prediction tasks, with the LR model leading in 3 tasks. Although GPT-4o mini achieved the highest AUPRC only in the asthma attack prediction, its average AUPRC value was 0.116, just 0.1% lower than GPT-3.5's best average of 0.117. In terms of AUROC, GPT-4o mini improved results by 3.1% compared to the LR and GPT-3.5 models. Note that the LR model showed significant performance drops in predicting atelectasis, pulmonary embolism, and angina, with AUROC values falling below 0.5. In contrast, GPT-4o mini demonstrated a more robust performance, with only the AUROC for angina dropping below 0.5. Table 4 presents the predictive performance of the LR, GPT-3.5, and GPT-4o mini models for the post-operative complication prediction tasks. Figure 4 illustrates the results more intuitively.

4 Discussion

In this study, we investigated the potential of large language models (LLMs) for predicting the prognosis of lung cancer patients. We focused on two key prediction tasks: survival and post-operative complications. To benchmark the performance of the LLMs, we also developed traditional data-driven models using logistic regression as a baseline for comparison.

Based on our experimental results, it is evident that large language models (LLMs) like GPT-4o mini and GPT-3.5 can achieve competitive, and in some tasks superior, predictive performance for lung cancer prognosis compared to traditional data-driven models. Note that LLMs do not require retrospective patient data to learn the latent patterns

Table 3: The AUROC and AUPRC values of the LR, GPT-3.5 and GPT-4o mini models for survival prediction.

Survival prediction tasks	AUROC			AUPRC		
	LR	GPT-3.5	GPT-4o mini	LR	GPT-3.5	GPT-4o mini
1-year survival prediction	0.710	0.706	0.732	0.093	0.073	0.099
2-year survival prediction	0.704	0.708	0.727	0.205	0.265	0.274
3-year survival prediction	0.730	0.695	0.716	0.402	0.299	0.383
4-year survival prediction	0.707	0.708	0.720	0.520	0.563	0.557
5-year survival prediction	0.719	0.715	0.735	0.660	0.645	0.693
Average	0.714	0.706	0.726	0.376	0.369	0.401




Figure 3: The AUROC (a) and AUPRC (b) values of the survival prediction models.

between features and outcomes. Instead, they leverage the extensive knowledge acquired from vast corpora to estimate the likelihood of outcomes based solely on the data of the current patient, which is like the decision-making process of a true clinician. No need for retrospective data is a significant advantage of LLMs in predicting clinical outcomes, especially given the value and scarcity of patient data, particularly for outcomes such as survival status and post-operative complications. Given their capability in prognosis prediction, LLMs can be utilized in more scenarios, even when patient data is limited or unavailable. Another critical advantage is that LLMs can provide explanations for their predictions, which is essential for gaining clinicians' trust and facilitating the adoption of AI models in clinical workflows to support decision-making.

Table 4: The AUROC and AUPRC values of the LR, GPT-3.5 and GPT-4o mini models for post-operative complication prediction.

Survival prediction tasks	AUROC			AUPRC		
	LR	GPT-3.5	GPT-4o mini	LR	GPT-3.5	GPT-4o mini
Atelectasis	0.390	0.486	0.546	0.015	0.065	0.025
Asthma attack	0.578	0.588	0.602	0.207	0.204	0.256
Pleural effusion	0.614	0.529	0.513	0.022	0.075	0.024
Lung infection	0.619	0.614	0.578	0.113	0.098	0.090
Pulmonary embolism	0.403	0.527	0.572	0.008	0.017	0.011
Deep vein thrombosis	0.741	0.606	0.670	0.201	0.135	0.179
Arrhythmia	0.523	0.614	0.629	0.029	0.077	0.070
Angina	0.403	0.301	0.459	0.012	0.014	0.009
Combined	0.608	0.558	0.591	0.376	0.369	0.375
Average	0.542	0.536	0.573	0.109	0.117	0.116




Figure 4: The AUROC (a) and AUPRC (b) values of the post-operative complication prediction models.

While the LLMs outperformed the baseline LR models in lung cancer prognosis prediction, it's essential to acknowledge that their superiority may not generalize to all clinical prediction tasks. The medical knowledge embedded in LLMs may vary across different diseases and clinical problems, which could affect their predictive performance. Moreover, the reasoning capabilities of LLMs differ due to variations in their training corpora and methodologies. In our study, the GPT-4o mini showed slightly better results than GPT-3.5, likely due to its more advanced design, as OpenAI stated. However, careful consideration and further exploration are necessary to determine which LLMs are best suited for particular clinical applications.

Additionally, we were unable to collect image data, such as pathology images, which are particularly valuable for predicting lung cancer prognosis. Although some studies have explored the use of LLMs like GPT-4 for diagnosing diseases from image data, these models have not yet shown strong performance in interpreting real-world medical images [34, 35, 36, 37]. In future work, we plan to collect relevant image data and investigate how to integrate them with clinical data to enhance the effectiveness of LLMs in clinical prediction tasks.

5 Conclusion

In this study, we evaluated the performance of LLMs in predicting the prognosis of lung cancer patients. Leveraging knowledge from extensive corpora, LLMs demonstrated competitive and, in some tasks superior, performance in survival and post-operative complication prediction tasks when compared to traditional data-driven logistic regression models. These results indicate that LLMs can effectively predict lung cancer outcomes without relying on extra retrospective patient data, highlighting their potential to offer a novel paradigm for clinical outcome prediction.

Acknowledgments

This work was supported by the Beijing Natural Science Foundation (L222020), the National Key R&D Program of China (No.2022YFC2406804), the Capital's funds for health improvement and research (No.2024-1-1023), and the National Ten-thousand Talent Program.

References

- [1] H. Sung et al., "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," *CA: A Cancer Journal for Clinicians*, vol. 71, no. 3, pp. 209-249, 2021.
- [2] J. A. Howington, M. G. Blum, A. C. Chang, A. A. Balekian, and S. C. Murthy, "Treatment of Stage I and II Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest

- Physicians Evidence-Based Clinical Practice Guidelines," *Chest*, vol. 143, no. 5, Supplement, pp. e278S-e313S, 2013.
- [3] Y. Huang, Z. Liu, L. He, X. Chen, D. Pan, Z. Ma, C. Liang et al., "Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non—Small Cell Lung Cancer," *Radiology*, vol. 281, no. 3, pp. 947-957, 2016.
 - [4] B. Li, Y. Cui, M. Diehn, and R. Li, "Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non—Small Cell Lung Cancer," *JAMA Oncology*, vol. 3, no. 11, pp. 1529-1537, 2017.
 - [5] Y. Wang, N. Wu, Q. Zheng, J. Wang, S. Yan, S. Li, Y. Liu et al., "Prediction of Surgical Outcome by Modeling Based on Risk Factors of Morbidity After Pulmonary Resection for Lung Cancer in Older Adults," *The Annals of Thoracic Surgery*, vol. 102, no. 3, pp. 971-978, 2016.
 - [6] C. Wang, S. Wang, Z. Li, and W. He, "A Multiple-Center Nomogram to Predict Pneumonectomy Complication Risk for Non-Small Cell Lung Cancer Patients," *Annals of Surgical Oncology*, vol. 29, no. 1, pp. 561-569, 2022.
 - [7] K. Kourou, T. P. Exarchos, K. P. Exarchos, M. V. Karamouzis, and D. I. Fotiadis, "Machine learning applications in cancer prognosis and prediction," *Computational and Structural Biotechnology Journal*, vol. 15, no. 13, pp. 8-17, 2015.
 - [8] J. Adeoye, J. Y. Tan, S.-W. Choi, and P. Thomson, "Prediction models applying machine learning to oral cavity cancer outcomes: A systematic review," *International Journal of Medical Informatics*, vol. 154, p. 104557, 2021.
 - [9] Y. Yu, Y. Tan, C. Xie, Q. Hu, J. Ouyang, Y. Chen, Y. Gu et al., "Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics–Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer," *JAMA Network Open*, vol. 3, no. 12, pp. e2028086-e2028086, 2020.
 - [10] J. Xiao, M. Mo, Z. Wang, C. Zhou, J. Shen, J. Yuan, Y. He et al., "The Application and Comparison of Machine Learning Models for the Prediction of Breast Cancer Prognosis: Retrospective Cohort Study," (in English), *JMIR Med Inform*, Original Paper vol. 10, no. 2, p. e33440, 2022.
 - [11] D. Hu, H. Zhang, S. Li, H. Duan, N. Wu, and X. Lu, "An ensemble learning with active sampling to predict the prognosis of postoperative non-small cell lung cancer patients," *BMC Medical Informatics and Decision Making*, vol. 22, no. 1, p. 245, 2022.
 - [12] B. Xue, D. Li, C. Lu, C. R. King, T. Wildes, M. S. Avidan, T. Kannampallil et al., "Use of Machine Learning to Develop and Evaluate Models Using Preoperative and Intraoperative Data to Identify Risks of Postoperative Complications," *JAMA Network Open*, vol. 4, no. 3, pp. e212240-e212240, 2021.
 - [13] B. Alsinglawi, O. Alshari, M. Alorjani, O. Mubin, F. Alnajjar, M. Novoa, and O. Darwish, "An explainable machine learning framework for lung cancer hospital length of stay prediction," *Scientific Reports*, vol. 12, no. 1, p. 607, 2022.
 - [14] J. L. Katzman, U. Shaham, A. Cloninger, J. Bates, T. Jiang, and Y. Kluger, "DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network," *BMC Medical Research Methodology*, vol. 18, no. 1, pp. 24-24, 2018.
 - [15] D. Hu, S. Li, Z. Huang, N. Wu, and X. Lu, "Predicting postoperative non-small cell lung cancer prognosis via long short-term relational regularization," *Artificial Intelligence in Medicine*, vol. 107, p. 101921, 2020.
 - [16] P. Mukherjee, M. Zhou, E. Lee, A. Schicht, Y. Balagurunathan, S. Napel, R. Gillies et al., "A shallow convolutional neural network predicts prognosis of lung cancer patients in multi-institutional computed tomography image datasets," *Nature Machine Intelligence*, vol. 2, no. 5, pp. 274-282, 2020.
 - [17] Y.-J. Tseng, H.-Y. Wang, T.-W. Lin, J.-J. Lu, C.-H. Hsieh, and C.-T. Liao, "Development of a Machine Learning Model for Survival Risk Stratification of Patients With Advanced Oral Cancer," *JAMA Network Open*, vol. 3, no. 8, pp. e2011768-e2011768, 2020.
 - [18] I. S. Hofer, C. Lee, E. Gabel, P. Baldi, and M. Cannesson, "Development and validation of a deep neural network model to predict postoperative mortality, acute kidney injury, and reintubation using a single feature set," *npj Digital Medicine*, vol. 3, no. 1, p. 58, 2020.
 - [19] A. Meyer, D. Zverinski, B. Pfahringer, J. Kempfert, T. Kuehne, S. H. Sündermann, C. Stamm et al., "Machine learning for real-time prediction of complications in critical care: a retrospective study," *The Lancet Respiratory Medicine*, vol. 6, no. 12, pp. 905-914, 2018.

- [20] D. Hu, B. Liu, X. Li, H. Chen, R. Guo, L. Cheng, X. Lu et al., "A Hierarchy-driven Multi-label Network with Label Constraints for Post-operative Complication Prediction of Lung Cancer*," presented at the 2023 45th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC), Sydney, Australia, 2023.
- [21] OpenAI. "Introducing ChatGPT." <https://openai.com/blog/chatgpt> (accessed March, 2024).
- [22] J. Achiam, S. Adler, S. Agarwal, L. Ahmad, I. Akkaya, F. L. Aleman, D. Almeida et al., "Gpt-4 technical report," arXiv preprint arXiv:2303.08774, 2023.
- [23] T. Brown, B. Mann, N. Ryder, M. Subbiah, J. D. Kaplan, P. Dhariwal, A. Neelakantan et al., "Language Models are Few-Shot Learners," in *Advances in Neural Information Processing Systems*, H. Larochelle, M. Ranzato, R. Hadsell, M. F. Balcan, and H. Lin, Eds., 2020, vol. 33, pp. 1877–1901.
- [24] L. Ouyang, J. Wu, X. Jiang, D. Almeida, C. Wainwright, P. Mishkin, C. Zhang et al., "Training language models to follow instructions with human feedback," in *Advances in neural information processing systems*, 2022, vol. 35, pp. 27730-27744.
- [25] L. Tang, Z. Sun, B. Idnay, J. G. Nestor, A. Soroush, P. A. Elias, Z. Xu et al., "Evaluating large language models on medical evidence summarization," *npj Digital Medicine*, vol. 6, no. 1, p. 158, 2023.
- [26] Y. Hu, Q. Chen, J. Du, X. Peng, V. K. Keloth, X. Zuo, Y. Zhou et al., "Improving large language models for clinical named entity recognition via prompt engineering," *Journal of the American Medical Informatics Association*, 2024.
- [27] R. Doshi, K. S. Amin, P. Khosla, S. Bajaj, S. Chheang, and H. P. Forman, "Quantitative Evaluation of Large Language Models to Streamline Radiology Report Impressions: A Multimodal Retrospective Analysis," *Radiology*, vol. 310, no. 3, p. e231593, 2024.
- [28] D. Hu, S. Zhang, Q. Liu, X. Zhu, and B. Liu, "The current status of large language models in summarizing radiology report impressions," arXiv preprint arXiv:2406.02134, 2024.
- [29] D. Hu, B. Liu, X. Zhu, X. Lu, and N. Wu, "Zero-shot information extraction from radiological reports using ChatGPT," *International Journal of Medical Informatics*, vol. 183, p. 105321, 2024.
- [30] P. Chung, C. T. Fong, A. M. Walters, N. Aghaepour, M. Yetisgen, and V. N. O'Reilly-Shah, "Large Language Model Capabilities in Perioperative Risk Prediction and Prognostication," *JAMA Surgery*, 2024.
- [31] B. S. Glicksberg, P. Timsina, D. Patel, A. Sawant, A. Vaid, G. Raut, A. W. Charney et al., "Evaluating the accuracy of a state-of-the-art large language model for prediction of admissions from the emergency room," *Journal of the American Medical Informatics Association*, 2024.
- [32] H. Changho, K. Dong Won, K. Songsoo, Seng, P. Jin Young, A. B. Sung, and Y. Dukyong, "Evaluation of GPT-4 for 10-year cardiovascular risk prediction: Insights from the UK Biobank and KoGES data," *iScience*, vol. 27, no. 2, p. 109022, 2024.
- [33] Y. Zhu, Z. Wang, J. Gao, Y. Tong, J. An, W. Liao, E. M. Harrison et al., "Prompting large language models for zero-shot clinical prediction with structured longitudinal electronic health record data," arXiv preprint arXiv:2402.01713, 2024.
- [34] Z. Yan, K. Zhang, R. Zhou, L. He, X. Li, and L. Sun, "Multimodal ChatGPT for medical applications: an experimental study of GPT-4V," arXiv preprint arXiv:2310.19061, 2023.
- [35] T. Nakao, S. Miki, Y. Nakamura, T. Kikuchi, Y. Nomura, S. Hanaoka, T. Yoshikawa et al., "Capability of GPT-4V(ision) in the Japanese National Medical Licensing Examination: Evaluation Study," (in English), *JMIR Med Educ*, Original Paper vol. 10, p. e54393, 2024.
- [36] Y. Zhou, H. Ong, P. Kennedy, C. C. Wu, J. Kazam, K. Hentel, A. Flanders et al., "Evaluating GPT-4V (GPT-4 with Vision) on Detection of Radiologic Findings on Chest Radiographs," *Radiology*, vol. 311, no. 2, p. e233270, 2024.
- [37] D. Brin, V. Sorin, Y. Barash, E. Konen, G. Nadkarni, B. S. Glicksberg, and E. Klang, "Assessing GPT-4 Multimodal Performance in Radiological Image Analysis," medRxiv, p. 2023.11.15.23298583, 2024.